Guardant Health, Inc. (GH) Cash Flow Statement

The OCF/NI ratio has hovered between 0.21 and 0.66 over the past year, with Q2 2026 at 0.48, meaning cash burn is roughly half the reported net loss. This suggests that while non-cash items like SBC and D&A inflate the loss, the underlying cash consumption remains substantial. Investors should monitor whether the gap narrows as revenue scales, but current trends indicate limited improvement in cash conversion quality.

FCF has been consistently negative across all ten quarters, with the most recent quarter showing a slight improvement from -23.6% in Q1 2026 but still far from breakeven. The trajectory suggests that revenue growth is not translating into cash generation, as operating expenses and working capital needs continue to outpace top-line gains. This implies that the company will require continued external financing to fund operations.

CapEx/Revenue has ranged from 1.8% to 9.9% over the past ten quarters, with no clear trend. The low average implies that the business does not require heavy fixed asset investment, consistent with a lab-based model. However, the occasional spikes may reflect investments in capacity or automation, which could signal future growth initiatives. Given the negative FCF, even modest CapEx adds to the cash burn, but the overall capital intensity appears manageable.

The working capital line has been erratic, with negative changes in most quarters but a large positive in Q4 2025. This suggests that the company's cash conversion cycle is unstable, possibly due to revenue recognition timing or payer reimbursement patterns. The negative working capital changes in recent quarters imply that cash is being tied up in receivables or inventory, exacerbating the cash burn. Investors should monitor whether this volatility stabilizes as the company scales.

The absence of dividends and buybacks is typical for a pre-profit company, but the single buyback in Q1 2025 is notable. That repurchase, while small relative to market cap, may indicate an opportunistic use of cash, but it does not signal a shift in capital allocation. The company is clearly prioritizing growth and R&D over shareholder returns, which is consistent with its stage. However, the ongoing cash burn means that external financing will be needed, potentially diluting existing shareholders.

The cumulative gap of over $500M between net income and operating cash flow highlights the substantial non-cash expenses, particularly stock-based compensation, which totaled over $400M in the same period. This divergence suggests that while the company is burning cash, the accounting losses overstate the cash drain. However, the cash burn is still severe, and the reliance on SBC to compensate employees may lead to dilution. The long-term implication is that the company must achieve profitability before its cash reserves are exhausted.